BR112015015509A2 - composto farmacêutico para a prevenção e tratamento de uma doença ou desordem cognitiva, neuro degenerativa ou doença neuronal - Google Patents
composto farmacêutico para a prevenção e tratamento de uma doença ou desordem cognitiva, neuro degenerativa ou doença neuronalInfo
- Publication number
- BR112015015509A2 BR112015015509A2 BR112015015509A BR112015015509A BR112015015509A2 BR 112015015509 A2 BR112015015509 A2 BR 112015015509A2 BR 112015015509 A BR112015015509 A BR 112015015509A BR 112015015509 A BR112015015509 A BR 112015015509A BR 112015015509 A2 BR112015015509 A2 BR 112015015509A2
- Authority
- BR
- Brazil
- Prior art keywords
- neurodegenerative
- cognitive
- treatment
- disorder
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/46—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
resumo composto farmacêutico para a prevenção e tratamento de uma doença ou desordem cognitiva, neuro degenerativa ou doença neuronal a presente invenção diz respeito a um composto farmacêutico com a fórmula (1), ou um seu sal farmaceuticamente aceitável, para utilização na prevenção ou tratamento de uma doença ou desordem cognitivas, neuro degenerativa ou distúrbio neuronal, tais como a doença de alzheimer, uma composição farmacêutica e um método de a preparação de uma composição farmacêutica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU92126 | 2012-12-31 | ||
| LU92126A LU92126B1 (fr) | 2012-12-31 | 2012-12-31 | Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale |
| PCT/EP2013/076936 WO2014102090A1 (en) | 2012-12-31 | 2013-12-17 | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015015509A2 true BR112015015509A2 (pt) | 2017-07-11 |
| BR112015015509B1 BR112015015509B1 (pt) | 2021-11-30 |
Family
ID=47470067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015015509-0A BR112015015509B1 (pt) | 2012-12-31 | 2013-12-17 | Composto farmacêutico para a prevenção e tratamento de uma doença ou desordem cognitiva, neuro degenerativa ou doença neuronal |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9284250B2 (pt) |
| EP (1) | EP2938337A1 (pt) |
| JP (1) | JP6699961B2 (pt) |
| KR (1) | KR102104155B1 (pt) |
| CN (1) | CN104884052B (pt) |
| AR (1) | AR094318A1 (pt) |
| AU (1) | AU2013369491B2 (pt) |
| BR (1) | BR112015015509B1 (pt) |
| CA (1) | CA2895429C (pt) |
| CL (1) | CL2015001881A1 (pt) |
| EA (1) | EA029650B1 (pt) |
| HK (1) | HK1214517A1 (pt) |
| IL (1) | IL239622B (pt) |
| JO (1) | JO3483B1 (pt) |
| LU (1) | LU92126B1 (pt) |
| MA (1) | MA38307B1 (pt) |
| MX (1) | MX369590B (pt) |
| MY (1) | MY171832A (pt) |
| NZ (1) | NZ710131A (pt) |
| PE (1) | PE20151424A1 (pt) |
| PH (1) | PH12015501402B1 (pt) |
| SG (1) | SG11201504744WA (pt) |
| TN (1) | TN2015000275A1 (pt) |
| TW (1) | TWI590819B (pt) |
| UA (1) | UA117822C2 (pt) |
| UY (1) | UY35253A (pt) |
| WO (1) | WO2014102090A1 (pt) |
| ZA (1) | ZA201505057B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2894542C (en) | 2012-12-21 | 2023-10-31 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CN110475853A (zh) * | 2017-01-13 | 2019-11-19 | 益福生医股份有限公司 | 新颖乳酸菌及其应用 |
| KR102017415B1 (ko) * | 2018-02-13 | 2019-09-02 | 연세대학교 산학협력단 | 뇌 신경 손상 완화용 조성물 |
| CN108813453A (zh) * | 2018-05-23 | 2018-11-16 | 青岛大学 | 一种防治帕金森病的食用组合物 |
| BR112022010141A2 (pt) | 2019-12-02 | 2022-08-09 | Philip Morris Products Sa | Dispositivo shisha com calha |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1261572A4 (en) * | 2000-03-10 | 2004-05-26 | Applied Genetics Inc Dermatics | DERMATOLOGICAL COMPOUNDS |
| CN1511520A (zh) * | 2002-12-31 | 2004-07-14 | �й�ҽѧ��ѧԺҩ���о��� | 丁二酸酯衍生物治疗痴呆症的用途 |
| RU2005131845A (ru) * | 2003-03-14 | 2006-02-10 | Мерк Шарп энд Домэ Лимитед (GB) | Способ лечения легкого ухудшения познавательной способности и предотвращения или задержки начала болезни альцгеймера |
-
2012
- 2012-12-31 LU LU92126A patent/LU92126B1/fr active
-
2013
- 2013-12-17 CN CN201380069044.3A patent/CN104884052B/zh active Active
- 2013-12-17 SG SG11201504744WA patent/SG11201504744WA/en unknown
- 2013-12-17 CA CA2895429A patent/CA2895429C/en active Active
- 2013-12-17 NZ NZ710131A patent/NZ710131A/en unknown
- 2013-12-17 EP EP13808014.8A patent/EP2938337A1/en active Pending
- 2013-12-17 MY MYPI2015702083A patent/MY171832A/en unknown
- 2013-12-17 EA EA201591021A patent/EA029650B1/ru unknown
- 2013-12-17 AU AU2013369491A patent/AU2013369491B2/en active Active
- 2013-12-17 MA MA38307A patent/MA38307B1/fr unknown
- 2013-12-17 US US14/758,343 patent/US9284250B2/en active Active
- 2013-12-17 WO PCT/EP2013/076936 patent/WO2014102090A1/en active Application Filing
- 2013-12-17 MX MX2015008520A patent/MX369590B/es active IP Right Grant
- 2013-12-17 BR BR112015015509-0A patent/BR112015015509B1/pt active IP Right Grant
- 2013-12-17 JP JP2015550024A patent/JP6699961B2/ja active Active
- 2013-12-17 KR KR1020157020805A patent/KR102104155B1/ko active IP Right Grant
- 2013-12-17 UA UAA201507037A patent/UA117822C2/uk unknown
- 2013-12-17 PE PE2015001180A patent/PE20151424A1/es unknown
- 2013-12-27 AR ARP130105072A patent/AR094318A1/es not_active Application Discontinuation
- 2013-12-30 UY UY0001035253A patent/UY35253A/es not_active Application Discontinuation
- 2013-12-30 JO JOP/2013/0390A patent/JO3483B1/ar active
- 2013-12-30 TW TW102148993A patent/TWI590819B/zh active
-
2015
- 2015-06-16 TN TNP2015000275A patent/TN2015000275A1/fr unknown
- 2015-06-18 PH PH12015501402A patent/PH12015501402B1/en unknown
- 2015-06-24 IL IL239622A patent/IL239622B/en active IP Right Grant
- 2015-06-30 CL CL2015001881A patent/CL2015001881A1/es unknown
- 2015-07-14 ZA ZA2015/05057A patent/ZA201505057B/en unknown
-
2016
- 2016-03-04 HK HK16102495.8A patent/HK1214517A1/zh unknown
- 2016-03-14 US US15/069,118 patent/US9611205B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015019720A2 (pt) | inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c | |
| CO2018009889A2 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| BR112015027055A8 (pt) | bi-heteroarilas, usos das mesmas, e composição farmacêutica | |
| EA201200002A1 (ru) | Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
| EA201500365A1 (ru) | Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| IN2014CN02959A (pt) | ||
| ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| BR112019003932A2 (pt) | composto, composição farmacêutica, combinação, método de tratamento de uma doença ou desordem e uso do composto | |
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| BR112017003571A2 (pt) | terapia combinada | |
| BR112015015509A2 (pt) | composto farmacêutico para a prevenção e tratamento de uma doença ou desordem cognitiva, neuro degenerativa ou doença neuronal | |
| BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
| BR112013033831A2 (pt) | composição farmacêutica oftalmológica tópica que contém regorafenib | |
| BR112015019919A2 (pt) | compostos bicíclicos | |
| BR112014029597A2 (pt) | compostos de cromano | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112014014802A2 (pt) | composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições | |
| BR112017020180A2 (pt) | derivados de aminohidrotiazina fundida em tetrahidrofurano que são úteis no tratamento da doença de alzheimer | |
| MX2010008706A (es) | Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales. | |
| BR112019005217A2 (pt) | terapia combinada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2013, OBSERVADAS AS CONDICOES LEGAIS. |